

Origin of Key Pharma Products (Ranked by FY22 Sales)

Key Products														
#1 Product	Humira	Enbrel	Tagrisso	Eliquis	Trulicity	Biktarvy	Shingrix	Stelara	Keytruda	Cosentyx	Ozempic	Comirnaty	Ocrevus	Dupixent
#1 Source	Acquired	Acquired	Organic	Acquired	Organic	Acquired	Organic	Acquired	Acquired	Organic	Organic	Licensed	Organic	Licensed
#2 Product	Botox	Otezla	Farxiga	Revlimid	Verzenio	Veklury	Xevudy	Darzalex	Gardasil	Entresto	Novorapid	Paxlovid	Perjeta	Flu Vaccine
#2 Source	Acquired	Acquired	Licensed	Acquired	Organic	Organic	Licensed	Licensed	Organic	Organic	Organic	Organic	Licensed	Organic
#3 Product	Skyrizi	Repatha	Imfinzi	Opdivo	Taltz	Genvoya	Triumeq	Invega	Lagevrio	Promacta	Tresiba	Eliquis	Hemlibra	DTaP vaccine
#3 Source	Licensed	Organic	Organic	Acquired	Organic	Acquired	Organic	Licensed	Licensed	Acquired	Organic	Licensed	Licensed	Organic
#4 Product	Imbruvica	Kyprolis	Lynparza	Pomalyst	Jardiance	Descovy	Trelegy	Imbruvica	Januvia	Gilenya	Victoza	Prevnar	Tecentriq	Lantus
#4 Source	Acquired	Acquired	Acquired	Acquired	Licensed	Acquired	Licensed	Licensed	Organic	Organic	Organic	Acquired	Organic	Acquired
#5 Product	Rinvoq	Neulasta	Symbicort	Orencia	Humalog	Harvoni	Nucala	Tremfya	Simponi	Tasigna	Rybelsus	Ibrance	Actemra	Aubagio
#5 Source	Organic	Organic	Organic	Acquired	Organic	Acquired	Organic	Organic	Licensed	Organic	Organic	Acquired	Licensed	Acquired
% Acquired / Licensed	80.0%	60.0%	40.0%	100.0%	20.0%	80.0%	40.0%	80.0%	60.0%	20.0%	–	80.0%	60.0%	60.0%
% of FY22 Sales	66.9%	40.6%	40.1%	80.9%	57.9%	73.7%	34.8%	53.8%	74.5%	30.6%	61.1%	74.4%	44.7%	47.1%
Market Cap (\$B)	\$260	\$138	\$212	\$129	\$525	\$96	\$72	\$428	\$282	\$235	\$328	\$207	\$246	\$136

Note: market data as of 8/23/2023